Research suggests that over 120,000 patients suffer from aortic arch disease in the US and Europe annually, but only around ...
Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the NEXUS (R) ...
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket ...
Endospan, an Israel-based developer of solutions for the endovascular repair of aortic arch disease, announced that the FDA ...
InvestorsHub on MSN
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition
Artivion Inc. (NYSE:AORT) said the U.S. Food and Drug Administration has approved the premarket application for the NEXUS ...
Zacks Investment Research on MSN
Artivion secures FDA approval for NEXUS aortic arch system
Artivion, Inc. AORT recently announced that the FDA has approved the premarket approval application for the NEXUS Aortic Arch ...
John Cantrell was enjoying his retirement until an unexpected condition forced him to choose between two kinds of heart ...
A study was conducted to determine the distribution and prevalence of extra-aortic aneurysms and dissections in adult patients with Marfan syndrome.
Aortic valve disease encompasses a spectrum of disorders affecting the aortic valve, with calcification being a hallmark of the most severe forms. Calcific aortic valve disease (CAVD) is characterised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results